잠시만 기다려 주세요. 로딩중입니다.

간이식 후 Hepatic Artery Thrombosis 예방 목적으로 투여된 Sarpogrelate과 Aspirin의 효과 및 안전성 비교

Clinical Efficacy and Safety of Sarpogrelate and Aspirin for Preventing Hepatic Artery Thrombosis After Liver Transplantation

병원약사회지 2020년 37권 3호 p.330 ~ 340
이은빈, 김효진, 김재송, 손은선, 유윤미,
소속 상세정보
이은빈 ( Lee Eun-Bin ) - Yonsei University College of Medicine Severance Hospital Department of Pharmacy
김효진 ( Kim Hyo-Jin ) - Yonsei University College of Medicine Severance Hospital Department of Pharmacy
김재송 ( Kim Jae-Song ) - Yonsei University College of Medicine Severance Hospital Department of Pharmacy
손은선 ( Son Eun-Sun ) - Yonsei University College of Medicine Severance Hospital Department of Pharmacy
유윤미 ( Yu Yun-Mi ) - Yonsei University College of Pharmacy

Abstract


Background : Hepatic artery thrombosis (HAT) is one of the most serious complications that can occur after liver transplantation. It is a major cause of graft loss. The aim of this study was to analyze the efficacy and safety of sarpogrelate and aspirin for preventing HAT after liver transplantation.

Methods : Electronic medical records of patients who had undergone their first liver transplantation at a tertiary hospital in Korea between August 1, 2016 and July 31, 2018 and received sarpogrelate or aspirin for HAT prevention were retrospectively reviewed. Iincidence of HAT and vascular complications and incidence of major bleeding events were selected as indicators for efficacy and safety, respectively.

Results : A total of 114 patients were included in this study. The incidence rate of HAT in the group receiving sarpogrelate or aspirin was 2.1 or 1.5%, respectively (p=0.820). No significant difference was also found in the incidence rate of portal vein thrombosis (p=0.481) or hepatic vein thrombosis (p=0.508) between the two groups. Although bleeding events with a decrease in hemoglobin level ≥ 3 g/dL in the aspirin group were significantly higher than those in the sarpogrelate group (p=0.032), the incidence of major bleeding events was not statistically different between the two groups (p=0.127).
Conclusion : There was no statistically significant difference in HAT prevention or major bleeding events between sarpogrelate and aspirin groups. Future research is needed to establish guidelines for the use of antiplatelet agents to prevent HAT in liver transplant patients.

키워드

Liver transplantation; Sarpogrelate; Aspirin; Hepatic artery thrombosis; Major bleeding

원문 및 링크아웃 정보

등재저널 정보